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Background  and  aims.  —  Portoenterostomy  is  the  initial  surgical  treatment  for  biliary  atresia
(BA); however,  no  curative  therapy  exists  for  BA.  Varix  bleeding  is  a  major  complication  of
end-stage liver  disease  and  must  be  determined  in  patients  with  BA,  necessitating  routine
surveillance  using  esophagogastroduodenoscopy  (EGD).  We  attempted  to  validate  criteria  to
identify BA  patients  requiring  EGD.
Methods.  —  From  January  2007  to  December  2017,  we  selected  BA  patients  who  underwent  Kasai
surgery,  transient  elastography  (TE),  and  EGD  at  Severance  hospital.  In  total,  190  cases  were
included; laboratory  tests  and  EGDs  were  carried  out  from  3  months  before  TE  to  3  months
after TE.
Results.  —  Based  on  the  cut-off  value  (<  10)  of  the  liver  stiffness  measurement  (LSM),  35  (81.4%)
patients with  low-risk  varix  (LRV)  and  8  (18.6%)  with  high-risk  varix  (HRV)  were  identified.  Based
on platelet  counts  (>  150,000),  87  (77.68%)  patients  with  LRV  and  25  (22.32%)  with  HRV  were
identified.  Based  on  this,  the  BAVENO  VI  criteria,  which  identify  patients  who  can  safely  avoid
screening EGD,  missed  9/68  (13.24%)  of  HRV  patients.  The  expanded  BAVENO  VI  criteria  missed
21/68 (30.88%)  of  HRV  patients.  However,  the  criteria  using  LSM  <10  and  platelet  count  >  150,000
missed identifying  only  4/68  (5.88%)  HRV  patients.
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Conclusions.  — The  BAVENO  criteria  may  be  as  useful  in  children  with  BA  as  in  adults  with
liver cirrhosis.  Regular  laboratory  tests,  imaging  studies,  and  EGD  may  avoid  missing  diagnoses
of varices  in  BA  patients.  However,  LSM  <  10  and  platelet  count  >  150,000  may  provide  more
accurate  criteria  and  help  identify  patients  who  does  not  need  endoscopy.
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iliary  atresia  (BA)  is  an  idiopathic  progressive  obliteration
f  the  hepatic  or  common  bile  duct  that  can  cause  neo-
atal  obstructive  cholangiopathy  in  the  first  month  of  life
1,2].  BA  is  a  rare  disease  with  unknown  etiology;  it  occurs
n  approximately  1.06  of  10,000  live  births  in  Korea  [3].
he  portoenterostomy  (Kasai)  procedure  was  introduced  as
he  initial  surgical  treatment  for  BA.  However,  no  curative
herapy  still  exists  for  BA  [4].  BA  is  the  leading  cause  of
nd-stage  liver  disease  and  an  indication  for  liver  transplan-
ation  in  children  [4,5].  Sequential  surgical  management
ith  the  Kasai  operation  followed  by  liver  transplantation
s  the  current  standard  of  care  for  patients  who  progress
o  end-stage  liver  disease.  Moreover,  esophageal  varix  is  a
ajor  complication  of  end-stage  liver  disease  to  be  deter-
ined  in  BA  patients.  Therefore,  it  is  essential  to  perform
outine  surveillance  such  as  esophagogastroduodenoscopy
EGD)  to  evaluate  for  esophageal  varix  [6—8].  However,  since
GD  is  invasive  procedure,  even  risk  is  mainly  related  to
nesthesia  in  patients  with  high  American  Society  of  Anes-
hesiologists  class,  a  non-invasive  test  to  identify  patients
equiring  EGD  may  be  beneficial  in  children  [9,10].
Degree  of  hepatic  fibrosis  status  can  be  assessed  through
aboratory  tests  and  liver  stiffness  measure  (LSM)  using
ransient  elastography  (TE)  [11].  Platelet  count  (PLT),  pro-
ein,  and  albumin  decrease  when  hepatic  fibrosis  increases.
oreover,  aspartate  transaminase,  alanine  aminotransfe-
ase  (ALT),  total  bilirubin,  direct  bilirubin,  gamma-glutamyl
ransferase  (GGT),  and  prothrombin  time  (international  nor-
alized  ratio;  INR)  may  be  increased  in  BA  patients  with
oor  hepatic  fibrosis.  In  adults,  the  BAVENO  VI  criteria
LSM  <  20  kPa  and  PLT  >  150,000  cells/L)  are  used  to  identify
ow  esophageal  varix  risk  in  patients  with  liver  cirrhosis  who
o  not  require  EGD  [12—14].  However,  there  are  no  valida-
ed  criteria  for  pediatric  patients,  especially  those  with  BA.
f  the  BAVENO  VI  criteria  can  be  applied  in  patients  with  BA
o  minimize  EGD  use,  continuous  follow-up  may  be  possible
hile  reducing  EGD-related  risks.
This  study  aimed  to  validate  the  BAVENO  VI  criteria  for  BA
atients  who  have  undergone  Kasai  surgery  to  safely  avoid
GD  for  esophageal  varix  surveillance.  Moreover,  we  aimed
o  identify  whether  alternative  combinations  of  LSM  and  PLT
hould  be  recommended  for  BA  patients.
ethodstudy  population
e  selected  BA  patients  who  had  undergone  Kasai  surgery






ecember  2017.  The  cases  were  included  if  the  laboratory
ests  and  EGD  were  done  from  3  months  before  TE  to  3
onths  after  TE.  BA  patients  in  whom  TE  was  performed
fter  undergoing  treatment  for  esophageal  bleeding  (band
igation,  sclerotherapy,  splenic  vessel  embolization,  or  LT)
ere  excluded  (Fig.  1).
ransient  elastography
atients  who  underwent  TE  were  included  only  if  the  LSM
as  measured  with  a  success  rate  >  60%  or  interquartile
ange  <  30%.  All  TE  procedures  were  performed  using  the
ibroScan  (Echosens,  Paris,  France)  by  a  professionally  trai-
ed  specialist  at  Severance  hospital.  The  median  value  of
uccessful  LSM  was  recorded  in  kilopascals  (kPa).  All  TE  pro-
edures  were  performed  with  the  patient  in  the  decubitus
osition,  through  the  intercostal  spaces,  to  measure  the
ight  lobe  of  the  liver.
sophagogastroduodenoscopy
ll  EGD  procedures  were  performed  by  the  endoscopists  at
everance  hospital.  The  varices’  status  was  described  accor-
ing  to  the  shape  and  size.  The  red  color  sign,  presence  of
astric  varix,  and  evidence  of  bleeding  were  recorded  accor-
ing  to  the  endoscopist’s  judgement.  A  low-risk  varix  (LRV)
as  defined  as  the  absence  of  varix  or  grade  1  esophageal
arix,  whereas  a  high-risk  varix  (HRV)  was  defined  as  grade
 or  higher  esophageal  varix,  any  gastric  varix  or  red  mark,
r  a  lesion  with  actual  bleeding.
aboratory  tests
e  retrospectively  reviewed  patient  records;  the  laboratory
est  (PLT,  TB,  DB,  AST,  ALT,  GGT,  and  INR)  results  closest  to
he  TE  date  were  selected.
tatistical  analysis
he  demographic  data,  laboratory  values,  and  LSMs  were
ompared  between  patients  with  and  without  the  risk  of
arix  bleeding.  The  normality  of  data  was  assessed  by
hapiro-Wilk  test.  In  the  case  of  continuous  variables  that
atisfy  the  normal  distribution,  mean  ±  SD  and  independent
-test  were  used  for  comparison.  In  the  case  of  non-normal
istribution,  the  medians  were  expressed  as  median  (Q1,
3).  For  categorical  variables,  we  used  the  chi-square  test
r  Fisher’s  exact  test  for  analysis.  Statistical  analyses  were
erformed  using  the  software  R  package,  version  3.4.4.

































Figure  1  Flow
Ethics  statement
The  Yonsei  Severance  Hospital  Institutional  Review  Board
approved  the  study  protocol  (No.  4-2018-0768).
Results
Baseline  characteristics
A  total  of  190  TE  were  performed,  with  EGD  and  blood
tests.  The  HRV  group  had  significantly  higher  birth-to-OP  and
OP-to-FibroScan  lengths  and  higher  INR  than  the  LRV  group
(P  <  0.05).
The  PLT,  ALT,  and  GGT  levels  were  significantly  lower  in
the  HRV  group  than  in  the  LRV  group  (P  <  0.05)  (Table  1).
Prevalence  of  patients  with  various  criteria
Several  LSM  and  PLT  criteria  were  used  to  identify  the  num-
ber  of  patients  included  in  each  risk  group.  Based  on  the
LSM  (cut-off  value  <  10),  43  cases  were  included,  of  which
35/43  (81.4%)  LRV  patients  and  8/43  (18.6%)  HRV  patients
were  identified.  Based  on  the  criteria  of  PLT  >  150,000,  87
(77.68%)  LRV  patients  and  25  (22.32%)  HRV  patients  were
included.  Consequently,  based  on  the  BAVENO  VI  criteria  to
identify  patients  who  can  safely  avoid  screening  with  EGD,
48  (84.21%)  LRV  and  9  (15.79%)  HRV  patients  were  included.
The  expanded  BAVENO  VI  criteria  identified  63  (75.00%)  LRV
and  21  (25.00%)  HRV  patients.  The  criteria  using  LSM  <  10  and
PLT  >  150,000  identified  33  (89.19%)  LRV  and  4  (10.81%)  HRV
patients  (Table  2).
Diagnostic  performance  of  each  criterionTable  3  demonstrates  the  usefulness  of  the  criteria  combi-
ning  LSM  and  PLT  to  predict  HRV  in  BA  patients.  We  missed




t  of  the  study.
n  using  the  BAVENO  VI  and  expanded  BAVENO  VI  criteria,
espectively.  However,  on  using  the  combined  LSM  <10  and
LT  > 150,000  criteria,  we  missed  diagnosis  in  only  4 patients
5.88%)  with  HRV.  The  sensitivity  of  the  BAVENO  VI  criteria
as  86.76,  while  that  of  the  new  combination  criteria  was
4.12.  The  negative  predictive  values  were  84.12,  75.00,
nd  89.19  for  the  BAVENO  VI,  expanded  BAVENO  IV,  and  new
ombined  criteria,  respectively.
iscussion
espite  the  introduction  of  the  reasonably  successful  Kasai
rocedure  as  a  surgical  treatment,  BA  is  today  the  most  com-
on  cause  for  liver  transplantation  in  children.  Moreover,
he  Kasai  operation  is  not  a curative  treatment  for  BA,  but
s  known  as  a  bridge  therapy,  which  is  performed  to  buy  time
efore  liver  transplantation.
Although  liver  transplantation  itself  is  a  high-risk  ope-
ation,  bleeding  due  to  esophageal  varices  carries  a  much
igher  risk  of  mortality  [4]. If  blood  tests,  TE,  and  EGD  can  be
erformed  every  3  or  6  months  every  year,  the  risk  of  blee-
ing  from  esophageal  varices  can  be  minimized  and  the  need
or  liver  transplantation  can  be  evaluated  closely.  Although
GD  is  the  most  accurate  method  of  identifying  varices,  EGD
tself  is  risky  because  of  the  sedation  process  that  is  requi-
ed  to  perform  this  procedure  in  children.  The  risk  of  side
ffects  is  not  high  if  a  single  EGD  is  performed.  However,  the
isk  can  increase  if  EGD  is  repeatedly  performed  to  identify
arices.  Therefore,  the  best  results  will  be  achieved  by  mini-
izing  the  number  of  EGDs  required;  this  can  be  achieved
y  performing  EGD  only  in  those  with  an  absolute  indica-
ion.  The  BAVENO  VI  criteria  are  used  in  adult  patients  with
irrhosis  to  identify  the  need  for  endoscopic  examinations.
owever,  to  the  best  of  our  knowledge,  no  such  criteria  existor  use  in  pediatric  patients.
In  the  present  study,  we  could  identify  the  basic  fea-
ures  of  patients,  which  are  provided  in  Table  1.  Similar  to
he  results  of  a  previous  study,  HRV  was  higher  in  patients
4  Y.  Kang  et  al.
Table  1  Baseline  characteristics.
Total  (n  =  190)  Low-risk  varix  (n  =  122)  High-risk  varix  (n  =  68)  P-value
Birth  OP  Day  62.00  (52.25,  73.75)  60.50  (47.75,  70.00)  64.00  (60.00,  82.25)  0.0038
OP FibroScan  Day  955.50  (341.50,  2154.75)  594.50  (264.75,  1932.50)  1314.00  (614.00,  2563.25)  0.0044
Gender 0.2475
Male 68  (35.79%)  40  (32.79%)  28  (41.18%)
Female 122  (64.21%)  82  (67.21%)  40  (58.82%)
PLT 180.00  (105.75,  254.00)  221.00  (145.50,  272.50)  125.50  (92.50,  177.50)  <  .0001
AST 90.00  (48.25,  148.75)  92.50  (54.00,  157.25)  79.00  (43.75,  130.25)  0.1512
ALT 68.50 (36.25,  121.75) 81.50  (40.25,  151.00)  55.00  (27.50,  92.75)  0.0046
Protein 6.30  (5.70,  6.70) 6.35  (5.70,  6.80) 6.30  (5.70,  6.53) 0.214
Albumin 3.71  (±0.58) 3.75  (±0.63) 3.64  (±0.49) 0.1532
TB 1.35  (0.60,  2.90)  1.20  (0.60,  3.00)  1.40  (0.60,  2.45)  0.7883
DB 0.80  (0.30,  2.20)  0.80  (0.30,  2.38)  0.70  (0.30,  1.65)  0.5267
GGT 145.50  (65.50,  315.50)  192.00  (82.75,  405.75)  100.00  (51.75,  222.25)  0.0050
INR 1.06  (0.98,  1.17)  1.04  (0.95,  1.14)  1.09  (1.03,  1.24)  0.0010
Esophageal varix  <  .0001
None 83  (43.68%)  68  (55.74%)  15  (22.06%)
Mild 67  (35.26%)  54  (44.26%)  13  (19.12%)
Moderate  27  (14.21%)  0  (0.00%)  27  (39.71%)
Severe 13  (6.84%)  0  (0.00%)  13  (19.12%)
Gastric varix  <  .0001
No 137  (72.11%)  122  (100.00%)  15  (22.06%)
Yes 53  (27.89%)  0  (0.00%)  53  (77.94%)
Red mark  <  .0001
No 179  (94.21%)  122  (100.00%)  57  (83.82%)
Yes 11  (5.79%)  0  (0.00%)  11  (16.18%)
Bleeding <  .0001
No 180  (94.74%)  122  (100.00%)  58  (85.29%)
Yes 10 (5.26%)  0  (0.00%)  10  (14.71%)
LSM 20.45  (10.80,  37.40) 20.00  (8.32,  34.70)  21.35  (12.45,  46.42)  0.0638
LSM.IQR 15.91  (8.71,  21.97)  16.00  (9.05,  21.00)  15.80  (7.72,  22.65)  0.6626
Continuous variables data that satisfy the normal distribution are presented as mean ± SD. In the case of non-normal distribution data
are presented as median (Q1, Q3). PLT: platelet; AST: aspartate transaminase; ALT: alanine aminotransferase; TB: total bilirubin; DB:
direct bilirubin; GGT: gamma-glutamyl transferase; INR: international normalized ratio; LSM: liver stiffness measurement.
Table  2  Prevalence  of  patients  with  various  criteria.
n  Low-risk  varix  High-risk  varix
LSM  <  10  43  35  (81.40%)  8  (18.60%)
LSM ≥  10  147  87  (59.18%)  60  (40.82%)
LSM <  15  67  46  (68.66%)  21  (31.34%)
LSM ≥  15 123  76  (61.79%)  47  (38.21%)
LSM <  20  92  61  (66.30%)  31  (33.70%)
LSM ≥  20 98  61  (62.24%)  37  (37.76%)
LSM <  25  110  72  (65.45%)  38  (34.55%)
LSM ≥  25  80  50  (62.50%)  30  (37.50%)
PLT >  150,000  112  87  (77.68%)  25  (22.32%)
PLT ≤  150,000  78  35  (44.87%)  43  (55.13%)
PLT >  110,000  140  101  (72.14%)  39  (27.86%)
PLT ≤  110,000  50  21  (42.00%)  29  (58.00%)
Within BAVENO  VI  criteria  57  48  (84.21%)  9  (15.79%)
Outside BAVENO  VI  criteria  133  74  (55.64%)  59  (44.36%)
Within expanded  BAVENO  VI  criteria  84  63  (75.00%)  21  (25.00%)
Outside expanded  BAVENO  VI  criteria  106  59  (55.66%)  47  (44.34%)
Within new  criteria  37  33  (89.19%)  4  (10.81%)
Outside new  criteria  153  89  (58.17%)  64  (41.83%)
Data are presented as n and percentage (%). LSM: liver stiffness measurement; PLT: platelet. New criteria: LSM < 10 and PLT > 150,000.
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Table  3  Diagnostic  performance  of  each  criterion.
BAVENO  VI  criteria  Expanded  BAVENO  VI  criteria  New  criteria
HRV  missed  9  (13.24%)  21  (30.88%)  4  (5.88%)
Sensitivity 86.76  (78.71,  94.82)  69.12  (58.14,  80.10)  94.12  (88.53,  99.71)
Specificity 39.34  (30.68,  48.01)  51.64  (42.77,  60.51)  27.05  (19.17,  34.93)
PPV 44.36  (35.92,  52.80)  44.34  (34.88,  53.80)  41.83  (34.01,  49.65)
NPV 84.21  (74.74,  93.68)  75.00  (65.74,  84.26)  89.19  (79.18,  99.19)
LR+ 1.43  (1.21,  1.70)  1.43  (1.12,  1.82)  1.29  (1.14,  1.46)







































Author contributionsData are presented as median (Q1, Q3). HRV: High-risk varix; PP
positive likelihood ratio; LR−:  negative likelihood ratio. New crite
who  were  older  at  the  time  of  Kasai  operation  [15].  In  addi-
tion,  the  risk  of  HRV  increased  with  time  after  surgery.  The
duration  from  Kasai  operation  to  FibroScan  was  significan-
tly  lower  in  the  LRV  group  than  in  the  HRV  group.  As  seen
in  this  study,  the  time  passed  after  the  Kasai  operation  was
positively  associated  with  HRV  [16].
Adami  et  al.  [17],  with  a  study  design  that  differs  from
our  own,  showed  platelet  count/spleen  size  z  score  ratio
can  be  used  to  screen  children  who  should  be  conside-
red  for  EGD.  The  result  was  similar  with  our  study.  The
platelet  counts  were  significantly  lower  in  the  HRV  group
than  in  the  LRV  group  in  this  study.  Thrombocytopenia
might  be  caused  by  liver  cirrhosis  and  splenomegaly.  The
ALT  was  high  in  the  LRV  group.  Liver  damage  can  lead
to  elevated  ALT  levels,  but  if  liver  cirrhosis  progresses,
ALT  levels  may  decrease,  which  may  lead  to  the  above
results.
Protein  and  albumin  levels  were  lower  in  the  HRV  group
than  in  the  LRV  group,  although  the  difference  was  not
statistically  significant.  However,  as  we  could  not  exclude
patients  with  IV  albumin  replacement,  albumin  levels  might
be  further  decreased  in  the  HRV  group.
In  Table  2,  we  present  several  criteria  to  determine  their
usefulness  in  BA  patients.  The  lower  the  value  of  LSM,  the
fewer  the  HRV  patients  were  included.  In  addition,  the
higher  the  value  of  PLT,  the  fewer  the  HRV  patients  included.
Similarly,  the  higher  the  value  of  the  standard,  the  lesser
the  HRV  patients  included.  In  addition,  when  using  the  cri-
teria  LSM  <  10  and  PLT  >  150,000,  which  are  more  stringent
than  the  BAVENO  criteria,  only  4  HRV  patients  were  inclu-
ded  [12,18].  Table  3  confirms  the  diagnostic  performance
of  each  criterion.  Among  the  HRV  patients,  the  diagnosis
was  missed  in  9,  21,  and  4  when  using  the  BAVENO  crite-
ria,  expanded  BAVENO  criteria,  and  combined  criteria  of
LSM  <  10  and  PLT  >  150,000,  respectively.  The  negative  pre-
dictive  value,  which  is  considered  to  be  the  most  important
among  these  criteria,  was  also  very  high  (89.19)  while  using
the  new  criteria.
In adults,  validation  of  the  BAVENO  criteria  was  perfor-
med  on  patients  with  cirrhosis.  Approximately  2%  of  the
BAVENO  criteria  were  mis-classified.  In  Korea,  HRV  were  mis-
classified  in  3.8%  when  using  the  BAVENO  criteria  for  people
with  cirrhosis  among  those  who  underwent  TE,  and  approxi-
mately  6.8%  were  mis-classified  using  expanded  BAVENO
criteria.  In  this  study,  the  BAVENO  criteria  were  applied
to  BA  children  and  mis-classified  5.88%  of  HRV  patients
and  missed  13.24%  of  HRV  when  the  expanded  BAVENO
C
a
ositive predictive value; NPV: negative predictive value; LR+:
LSM < 10 and PLT > 150,000.
riteria  were  applied.  However,  when  applying  the  LSM  <  10
nd  PLT  >  150,000  criteria,  only  5.88%  of  HRV  patients  were
is-classified.  However,  5.88%  is  higher  than  2%  and  3.8%,
hich  were  the  rates  of  mis-classification  in  adult  cirrhosis
atients  and  Korean  adult  patients  with  cirrhosis,  respecti-
ely.  However,  the  new  criteria  may  be  used  as  an  objective
ethod  to  identify  the  BA  patients  who  can  avoid  EGD  scree-
ing.
Some  limitations  were  present  in  this  study.  First,  this
tudy  only  involved  retrospective  reviewing  of  the  records  of
 single  institution.  Hence,  the  actual  usefulness  of  the  new
riteria  cannot  be  confirmed  without  a  prospective  study.
econd,  the  results  of  the  FibroScan  and  EGD  performed
ultiple  times  in  one  patient  was  included  as  a  single  case,
eflecting  individual  characteristics.  Third,  the  EGD,  FibroS-
an,  and  laboratory  tests  were  not  performed  regularly  in
atients.  Moreover,  patients  with  problems,  such  as  cholan-
itis  or  infection  may  have  undergone  EGD  and  FibroScan
ore  times,  which  might  have  caused  a  selection  bias.
However,  despite  these  limitations,  this  is  the  first  study,
o  the  best  of  our  knowledge,  to  confirm  the  usefulness  of
he  BAVENO  criteria  in  children  with  BA,  and  it  seems  to  be
n  objectively  groundbreaking  study  for  identifying  patients
ho  need  EGD.  However,  it  is  not  recommended  to  use  only
hese  criteria  because  it  can  be  fatal  if  we  miss  diagnosing
atients  with  varices.  Moreover,  patients  who  need  EGD  can
e  more  accurately  selected  if  patients  with  known  poor
rognostic  factors  (e.g.,  Kasai  operation  done  in  patients
lder  than  2  months,  recurrent  cholangitis)  are  examined
arefully.
In  conclusion,  the  BAVENO  criteria  could  be  as  useful
n  children  with  BA  as  in  adults.  However,  regular  labora-
ory  tests,  imaging  studies,  and  EGD  must  be  performed
o  that  varices  in  BA  patients  are  not  missed.  Further,
asing  patient  classification  on  the  criteria  of  LSM  <  10  and
LT  > 150,000  would  be  more  accurate  and  objective  for
dentifying  patients  who  does  not  need  endoscopy.
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